We use some essential cookies to make this site work. We’d also like to use analytics cookies to understand how people use the site, and to show content from other sites, such as YouTube videos, which set their own cookies. We won’t set these unless you agree. You can change your choice at any time using “Cookie settings” at the bottom of every page.
Find out more about cookies
Choose which cookies you’re happy for us to use. Your choice
applies to the whole site and lasts for
6 months.
Cookie categories
Category
Switch
Description
Necessary
Always on
Needed for the site to work, for example to keep you logged in and protect the site from attacks. These can’t be turned off.
Help us understand how people use the site, such as which pages they visit, so we can improve it. The information is collected by Google Analytics and doesn’t identify you.
Let us show videos, maps and posts from other sites, such as YouTube, Vimeo and X (Twitter). These sites may set their own cookies and track what you do.
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
Mascarenhas JO., Prchal JT., Rambaldi A., Mesa RA., Berenzon D., Yacoub A., Harrison CN., McMullin MF., Vannucchi AM., Ewing JC., O'Connell CL., Kiladjian J-J., Mead A., Winton EF., Leibowitz DS., De Stefano V., Arcasoy MO., Kessler CM., Catchatorian R., Rondelli D., Silver RT., Ritchie EK., Nagler A., Kremyanskaya M., Schlenk RF., Weinberg RS., Salama ME., Tognoni G., Prosperini G., Di Lelio A., Serone E., Marfisi L., Kleczko J., Kosiorek HE., Barbui T., Dueck AC., Hoffman R.